Gernandt & Danielsson advises Orexo AB (publ) (“Orexo”) in its issue of senior unsecured bonds in an amount of SEK 500 million within a framework amount of SEK 1 billion. Orexo intends to apply for admission to trading of the bonds on the corporate bond list of Nasdaq Stockholm. In connection with the bond issue, Orexo has repurchased outstanding bonds in an aggregate amount of SEK 77.4 million and called for redemption of the residual of such outstanding bonds.

Orexo develops improved pharmaceuticals and digital therapies addressing the growing space of substance use disorders and mental health. The main market today is the US market for buprenorphine and naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Orexo’s shares are listed on Nasdaq Stockholm, Mid Cap (ORX), and is available as ADRs on OTCQX (ORXOY) in the US.

Gernandt & Danielsson has advised the company and its financial advisor ABG Sundal Collier with a team consisting of Partner Mikael Borg, Senior Associate Maria Klaesson and Associate Camilla Hedner.